Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

GlaxoSmithKline's pitch to shareholders kicked ... 2 billion plus in sales for HIV pre-exposure prophylaxis (PrEP) drug Cabenuva (cabotegravir), hepatitis B virus (HBV) antisense drug GSK3228836 ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...

Teva Pharmaceutical Industries Ltd. ADR-1.51% $18.8B ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

After hours: 7:44:54 p.m. EST ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...